Hey everyone,
I want to start today by following up on something I talked about recently.
Last Sunday, I wrote about Hyperion DeFi (HYPD) and walked through what it had been doing over the past few months. Since then, I’ve been checking in on it throughout the week to see how it behaved once the initial attention faded.
So far, it’s been a solid week.
Over the last few trading sessions, HYPD moved from the low $3.00s into the $3.50 range, putting it up roughly 15%. What stood out to me wasn’t just the move, but the way it behaved afterward. It pushed higher, pulled back, and then held those levels instead of giving everything back. That kind of action tends to show up when buyers are still present, even as short-term traders step aside.
That was especially noticeable during a week where much of the market’s attention was tied up in interest rates, shifting Fed expectations, and how funds were positioned heading into month-end. Not everything was getting rewarded, and not every chart looked healthy.
Watching which stories held together and which ones didn’t was useful.
Which brings me to the next company I’ve been spending time on.
PetVivo Holdings, Inc. (PETV) is moving on a very different timeline.
PetVivo operates in animal health, developing veterinary products used by clinics to treat joint issues and mobility problems in animals.
Over the past few months, the company has been quietly putting out a steady stream of updates. None of them were meant to grab headlines on their own. They felt more like pieces of groundwork being laid one at a time.
It started with visibility.
PetVivo showed up at investor conferences and industry events, including presenting at capital markets conferences. That usually signals a company still in capital-building mode, but it also tells you management wants to stay visible and engaged rather than disappear between filings.
They were also making sure they were visible where it matters operationally.
By exhibiting at veterinary and equine conferences, PetVivo put itself directly in front of practitioners, not just investors. Adoption in animal health is slow and relationship-driven. Products get used because vets trust them, not because they read a press release.
Then came the financial reality checks.
In their earnings releases, PetVivo hasn’t tried to dress anything up. The company is still operating at a loss, and spending has increased as it pushes sales and distribution.
That said, revenue is showing measurable improvement. In fiscal Q2 2026, revenue rose to about $303,000, up more than 50% from the same quarter a year earlier. For the first half of the fiscal year, revenue climbed roughly 85% year over year to just over $600,000.
These are still small numbers, but the growth is being driven by broader distributor reach, new product contributions, and expanding exposure beyond the equine market. At this stage, consistency and direction matter more than scale.
At the same time, they were working on the less visible parts of the business.
Through distribution agreements and vendor partnerships, PetVivo focused on making Spryng easier for clinics to access and reorder. This kind of work rarely moves a stock, but it often determines whether a product ever reaches meaningful scale.
On January 21, the company added a new layer to the story.
Instead of another update centered on Spryng, PetVivo announced an AI-driven platform aimed at helping veterinary clinics manage outreach, engagement, and growth. This wasn’t positioned as a replacement for their core business, but as an expansion around how clinics operate day to day.
Seen alongside the rest of the past few months, that announcement reads less like a pivot and more like an extension. Management appears to be testing whether PetVivo can move beyond being product-led and into a broader role supporting how clinics operate.
For now, the business is still anchored by Spryng. While PetVivo lists multiple product candidates in its pipeline, Spryng remains the only product generating revenue today, with the rest still in development.
To be clear, this isn’t a clean or obvious setup.
PetVivo is early, it’s still losing money, and the path forward depends heavily on execution. That’s the reality.
What caught my attention is that the past few months look intentional. Conference presence, distribution work, product expansion, and now software. It’s not fast, but it’s deliberate.
That’s why I spent time taking a closer look and will keep up with it in the meantime. If anything changes or stands out, I’ll be sure to share it.
Next week, I’m going to turn my attention to Pelican Acquisition Corp, so be on the lookout for that.
Invest your best,
Brandon Parks.
Disclaimer: The information in this communication is for informational and educational purposes only and does not constitute financial, legal, or tax advice. I am not a licensed financial advisor. The views, ideas, and any security mentions expressed are my personal opinions, are subject to change, and are not a recommendation to buy or sell. No warranty is made regarding the accuracy or completeness of this information. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal. You should consult a qualified financial professional to determine the suitability of any investment for your specific situation and always conduct your own due diligence. Neither I nor Earnings Alpha shall be held liable for any losses or damages arising from any action taken based on this content. We do not currently hold positions in the securities mentioned above.